Cargando…

Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients

Detalles Bibliográficos
Autores principales:	Chaulagain, Chakra P., Diacovo, Julia M., Elson, Leah, Comenzo, Raymond L., Samaras, Christy, Anwer, Faiz, Khouri, Jack, Landau, Heather, Valent, Jason
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183688/ https://www.ncbi.nlm.nih.gov/pubmed/32029395 http://dx.doi.org/10.1016/j.clml.2019.12.022

Ejemplares similares

Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
por: Dima, Danai, et al.
Publicado: (2023)

Predictors of Hospitalizations and Death from COVID-19 in Patients with Multiple Myeloma
por: Chaulagain, Chakra P, et al.
Publicado: (2022)

Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia)
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Liver failure due to relapsed myeloma and hepatic iron overload
por: Chaulagain, Chakra P, et al.
Publicado: (2020)

Management of Primary Plasma Cell Leukemia Remains Challenging Even in the Era of Novel Agents
por: Chaulagain, Chakra P, et al.
Publicado: (2021)

Challenges of Managing Multiple Myeloma Patients with Sickle Cell Disease: A Case Report and Review of Literature
por: Zerdan, Maroun Bou, et al.
Publicado: (2021)

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth
por: Ma, Xun, et al.
Publicado: (2018)

Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
por: Chakraborty, Rajshekhar, et al.
Publicado: (2021)

Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase
por: Awada, Hussein, et al.
Publicado: (2023)

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
por: Dima, Danai, et al.
Publicado: (2020)

A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma
por: Chakraborty, Rajshekhar, et al.
Publicado: (2020)

Overwhelming Asplenic Sepsis due to Babesiosis
por: Chaulagain, Chakra P.
Publicado: (2019)

Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
por: Xu, Xu Steven, et al.
Publicado: (2018)

Liquid biopsies and minimal residual disease in myeloid malignancies
por: Allam, Sabine, et al.
Publicado: (2023)

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)

Clonal evolution in therapy-related neoplasms
por: Fabiani, Emiliano, et al.
Publicado: (2017)

Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
por: Kjær, Lasse
Publicado: (2020)

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
por: Xu, XS, et al.
Publicado: (2017)

Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma
por: Durie, Brian G. M., et al.
Publicado: (2020)

Daratumumab Interferes with Allogeneic Crossmatch Impacting Immunological Assessment in Solid Organ Transplantation
por: Ho, Chak-Sum, et al.
Publicado: (2022)

Systemic AL amyloidosis: current approach and future direction
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Addendum: Systemic AL amyloidosis: current approach and future direction
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
por: Mian, Hira, et al.
Publicado: (2022)

A Novel Daratumumab-Based Regimen for Desensitization in Highly HLA-Presensitized Patients Awaiting Kidney Transplantation
por: Zhao, Daqiang, et al.
Publicado: (2023)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Elevated Incidence of Fractures in Solid-Organ Transplant Recipients on Glucocorticoid-Sparing Immunosuppressive Regimens
por: Edwards, B. J., et al.
Publicado: (2011)

Efficacy of Daratumumab-Based Regimens Compared to Standard of Care in Transplant-Eligible Multiple Myeloma: A Meta-Analysis
por: Menon, Trishala, et al.
Publicado: (2021)

A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone
por: Kuan, Jew Win, et al.
Publicado: (2022)

Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
por: Sokolova, Alexandra, et al.
Publicado: (2017)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Infection Risk Associated with Daratumumab
por: Johnsrud, Joyce J, et al.
Publicado: (2017)

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm
por: Fleischman, Angela G.
Publicado: (2015)

Therapy-Related Myeloid Neoplasms: Predisposition and Clonal Evolution
por: Fabiani, Emiliano, et al.
Publicado: (2023)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Multidisciplinary supportive care in systemic light chain amyloidosis
por: Maroun, Bou Zerdan, et al.
Publicado: (2022)

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2017)

Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials
por: Htut, Thura W., et al.
Publicado: (2020)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rddfil76o1ktblq2udibkuimum